This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | |||
home:patients:protocol_overview [06.24.2019] – [Introduction to the Marshall Protocol] sallieq | home:patients:protocol_overview [01.16.2020] – sallieq | ||
---|---|---|---|
Line 5: | Line 5: | ||
- | The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and almost 100% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases. | + | The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and over 85% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases. |
Treatment on the MP requires a [[home: | Treatment on the MP requires a [[home: |